

## Herpes-simplex-Infektionen der Haut

### Infections cutanées à Herpes simplex

#### Literatur / Références

- 1 Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. *AIDS* 2006;20:73–83.
- 2 Schiffer JT, Corey L. New concepts in understanding genital herpes. *Curr Infect Dis Rep* 2009;11:457–64.
- 3 Garceau R, Leblanc D, Thibault L, Girouard G, Mallet M. Herpes simplex virus type 1 is the leading cause of genital herpes in New Brunswick. *Can J Infect Dis Med Microbiol* 2012;23:15–8.
- 4 Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. *N Engl J Med* 1999;341:1432–8.
- 5 Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. *Ann Intern Med* 1992;116:197–202.
- 6 Lautenschlager S, Quack K, Weber R, Eichmann A. Epidemiologie der Infektion mit Herpes simplex Viren (HSV-1 und HSV-2) in unterschiedlichen Kollektiven. *Dermatology* 2001;203:95–6.
- 7 Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. *Ann Intern Med* 1999;131:14–20.
- 8 Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. *Ann Intern Med* 1994;121:847–54.
- 9 Ashley RL, Wald A. Genital herpes: Review of the epidemic and potential use of type-specific serology. *Clin Microbiol Rev* 1999;12:1–8.
- 10 Lautenschlager S, Eichmann A. The heterogeneous clinical spectrum of genital herpes. *Dermatology* 2001;202:211–9.
- 11 Lautenschlager S, Eichmann A. Urethritis: an underestimated clinical variant of genital herpes in men? *J Am Acad Dermatol* 2002;46:307–8.
- 12 Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. *N Engl J Med* 2000;342:844–50.
- 13 Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. *Ann Intern Med* 1996;124:8–15.
- 14 Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. *J Antimicrob Chemother* 2000;45 Suppl T3:1–8.
- 15 Gupta R, Warren T, Wald A. Genital herpes. *Lancet* 2007;370:2127–37.
- 16 Ross K, Johnston C, Wald A. Herpes simplex virus type 2 serological testing and psychosocial harm: a systematic review. *Sex Transm Infect* 2011;87:594–600.
- 17 Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. *Arch Intern Med* 2008;168:1137–44.
- 18 van der Bij AK, Spaargaren J, Morre SA, Fennema HS, Mindel A, Coutinho RA, et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. *Clin Infect Dis* 2006;42:186–94.
- 19 Spruance SL, Bodsworth N, Resnick H, Conant M, Oeuvray C, Gao J, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. *J Am Acad Dermatol* 2006;55:47–53.
- 20 Swiss Herpes Management Forum. Swiss recommendations for the management of genital herpes and herpes simplex virus infection of the neonate. *Swiss Med Wkly* 2004;134:205–14.
- 21 Patel R, Alderson S, Geretti A, Nilsen A, Foley E, Lautenschlager S, et al. European guideline for the management of genital herpes, 2010. *Int J STD AIDS* 2011;22:1–10.
- 22 Corey L, Stanberry L. Recommendations for short-course therapies in herpes genitalis and herpes labialis. *Herpes* 2007;14 Suppl 1:4A.

- 23 Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. *Clin Infect Dis* 2002;34:958–62.
- 24 Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. *Clin Infect Dis* 2002;34:944–8.
- 25 Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 2006;42:8–13.
- 26 Bavaro JB, Drolette L, Koelle DM, Almekinder J, Warren T, Tyring S, et al. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. *Sex Transm Dis* 2008;35:383–6.
- 27 Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. *J Am Acad Dermatol* 2007;57:238–46.
- 28 Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. *N Engl J Med* 2007;356:790–9.
- 29 Wilkinson E. Herpes treatment may limit HIV transmission and progression. *Lancet Infect Dis* 2007;7:249.
- 30 Wald A, Selke S, Warren T, Aoki FY, Sacks S, Diaz-Mitoma F, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. *Sex Transm Dis* 2006;33:529–33.
- 31 Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. *J Clin Invest* 2011;121:4600–9.
- 32 Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. *JAMA* 2001;285:3100–6.
- 33 Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. *N Engl J Med* 2004;350:11–20.
- 34 Field HJ, Mickleburgh I. The helicase-primase complex as a target for effective herpesvirus antivirals. *Adv Exp Med Biol* 2013;767:145–59.